科伦博泰生物-B(06990):SKB445新药临床试验申请获国家药品监督管理局批准

智通财经
20 Jan

智通财经APP讯,科伦博泰生物-B(06990)发布公告,该公司董事会欣然宣布,公司已于2025年1月20日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB445新药临床试验申请的临床试验通知书。

SKB445是一款由公司针对靶点生物学特点,利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物,在临床前研究中显示出良好的疗效和安全窗,拟用于治疗晚期实体瘤。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10